According to FMI – an ESOMAR-certified market research firm, the global oligonucleotide API market is estimated to reach US$ 3 Bn in 2020, and witness a CAGR of 11% through 2030.

According to FMI’s analysis, as of now, 100+ oligonucleotide APIs are in the clinical trials’ phase, and regulatory approval is on the cards. Post-approval, the demand for production capacity will witness an exponentiation, thereby driving the oligonucleotide API market through 2030.

Some of the key oligonucleotide classes are antisense oligonucleotides, micro-RNA, small/short interfering RNA, immunostimulatory oligonucleotides, splice-switching oligonucleotides, and aptamers. Some of the factors that have boosted the trend of oligonucleotide APIs in solution are solution stability, viscosity, concentration, end-to-end manufacturing, and packaging.

Progress made in industry associations sharing of CMC (chemistry, manufacturing, and control) strategies is boosting the prospect in the oligonucleotide APIs market. Growing demand for new drug classes for COPD (Chronic Obstructive Pulmonary Disease) and asthma has unlocked new avenues in the market

Key Takeaways from Oligonucleotide API Marker Study

• Antisense Oligonucleotides APIs are anticipated to reach US$ 4 Bn by 2030.
• North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
• Increase in use of antisense oligonucleotide APIs (especially post approval from US FDA in 2016) to boost the market in the forecast period

Covid-19 Impact on Oligonucleotide Market

The outbreak of Covid-19 has temporarily stalled the oligonucleotide API market as the production has slowed down owing to partial/total lockdown worldwide. However, the market is expected to bounce back after subsequent two quarters. By then, players are likely to invest more in oligonucleotide APIs to look for long-term solution to pandemics like these.

Oligonucleotide API Market: Segmentation

API Type

• Antisense Oligonucleotides API
• Short Interfering RNA (siRNA) API
• Phosphorodiamidate Morpholino Oligonucleotides (PMO) API
• MiRNA API
• Aptamers API
• CpG Oligonucleotides API
• Others (ON Conjugates (NP), ShRNA, etc.)

Marketing Status

• Marketed
• Clinical Trials (Clinical Phases)

End User

• Contract Manufacturing Organizations (CMOs)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• MEA

Global Oligonucleotide API Market: Competitive Analysis

Research in utilizing oligonucleotides in infectious and genetic diseases has spurred new therapeutic strategies in the oligonucleotide APIs market. Several pharma companies over the past 10 years have rebuffed their efforts in utilizing the potential. To this end, they have been notably ramped up their investments in expanding their production capacities.

Corden Pharma GmbH, a German pharma company, has announced to make manufacturing capacity expansion in Colorado, U.S. The capacity expansion notably includes the synthesis and purification of the concentrate. The company has aimed at offering companies manufacturing services expanding their drug development programs in clinical trials.

As many as oligonucleotide programs are in development in 2019, moving from research through Phase III. This accounts for the vast investment potential for pharma companies in the oligonucleotide APIs market.

Some of the promising industry players in the oligonucleotide APIs market are Biogen, GE Healthcare Life Sciences, and Nitto Denko Avecia.